Close

Edwards Lifesciences (EW) Announces FDA Approval of SAPIEN XT for Aortic Valve-in-Valve Procedures

Go back to Edwards Lifesciences (EW) Announces FDA Approval of SAPIEN XT for Aortic Valve-in-Valve Procedures

Edwards SAPIEN XT Valve Receives FDA Approval For Aortic Valve-In-Valve Procedures

October 15, 2015 3:15 PM EDT

IRVINE, Calif., Oct. 15, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) approval for aortic valve-in-valve procedures using the Edwards SAPIEN XT transcatheter heart valve.

"U.S. approval of the valve-in-valve procedure provides an important minimally invasive treatment option for patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valves," said Larry L. Wood, Edwards'... More